reverse phase arrays

Zeptosens, owned by Bayer Technology Services, provides protein profiling services using reverse phase arrays. The principle allows comparative, multiparallel evaluation of several hundred samples for

• modulation of signaling pathway activity monitoring
• cell based compound selectivity & inhibition profiling
• preclinical toxicology
• drug mechanism studies
• protein profiling in healthy versus diseased human tissue
• biomarker / target discovery and validation

An integrative part of the technology is a planar waveguide based fluorescence detector which only interacts with bound analytes on the chip surface. This significantly increases the signal-to-noise ratio and enables to monitor expression & signaling changes for low-abundance proteins in just 400 pL of spotted cell or tissue lysate. The generated information of this array-based method is equivalent to > 10,000 quantitative Western Blot lanes being processed in only one week and at a fraction of antibody material. Read more...